Idt Australia Limited

IDT.ASX

Health Care

Supply of products and provision of research and development and other technical services for the pharmaceutical and allied industries.

Market Data

Price

$0.037

+0.0%
Market Cap

$15.8M

P/E Ratio

-100000.0x

EPS

$-0.014

Div. Yield

0.00%

52-Week Change

-0.5%

Latest Earnings

1HFY26 Appendix 4D and Half Year Report

18 February 2026

Revenue
$9.80
-7.0% YoY
NPAT
-$1.32
+59.5% YoY
EPS
$-0.00

IDT Australia's loss narrowed significantly by 59.5% to $1.3 million in H1FY26, the strongest profitability metrics since its strategic transformation began over two years ago. While revenue declined 7% to $9.8 million, improved operational efficiency drove the better result, with positive operating cash flow of $1.6 million and strengthened cash position to $1.9 million. Key points: Loss narrowed significantly by 59.5% to $1.3 million, strongest profitability metrics since strategic transformation; Strong cash flow turnaround with $1.6 million operating cash inflows vs $5.2 million outflow in prior year; API Manufacturing grew strongly by 191.4% to $3 million, Specialty Orals up 26% to $2.5 million

Recent Announcements

28 Apr 2026 Guidance Positive

March Quarter Update & Positive FY26 Guidance

IDT Australia Limited (ASX: IDT) reported that FY26 EBITDA losses are forecast to narrow materially to $1.5M-$2M (a 68-76% improvement on FY25's $6.3M loss) with revenue expected between $15M-$16M, supported by Sanofi's Preferred Vendor designation, favorable US policy shifts for psychedelics/cannabis, recommissioned facilities, and a strategic partnership with Fierce Pharma to access global pharmaceutical markets.

18 Feb 2026 Actual Results Positive

1HFY26 Appendix 4D and Half Year Report

IDT Australia's loss narrowed significantly by 59.5% to $1.3 million in H1FY26, the strongest profitability metrics since its strategic transformation began over two years ago. While revenue declined 7% to $9.8 million, improved operational efficiency drove the better result, with positive operating cash flow of $1.6 million and strengthened cash position to $1.9 million. Key points: Loss narrowed significantly by 59.5% to $1.3 million, strongest profitability metrics since strategic transformation; Strong cash flow turnaround with $1.6 million operating cash inflows vs $5.2 million outflow in prior year; API Manufacturing grew strongly by 191.4% to $3 million, Specialty Orals up 26% to $2.5 million

Get real-time alerts for IDT

Receive AI-powered earnings summaries and instant notifications when Idt Australia Limited releases results.

Register Free